ArticleHeliyon2024

Case report: A promising neoadjuvant treatment option for individuals with locally advanced HER2-positive breast cancer involves the use of Pyrotinib Maleate in combination with Trastuzumab and Pertuzumab.

Chi Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.